Company / Return on Equity (ROE)
Altimmune, Inc. Return on Equity (ROE) History
FY2011-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Return on Equity (ROE)
-39.2%
FY2025
5-year range
-48.8% / -21.7%
FY2021-FY2025
Trend
+14.0%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Altimmune, Inc. reports negative total equity of -39.2% in FY2025. Negative equity can occur when accumulated losses exceed contributed capital, as reported in the balance sheet from the SEC filing.
Based on SEC 10-K filings.
-39.2% in FY2025 with a 5-year CAGR of +5.9%.
Improved from -45.7% to -39.2% over the past 2 years.
Return on Equity (ROE) over time
Growth rates
- 3-Year Change
- +9.6pp
- 5-Year Change
- +5.9pp
- 10-Year Change
- -
Key checks
Key Insights
- Altimmune, Inc.'s return on equity (roe) has grown for 3 consecutive years.
- In FY2025, return on equity (roe) increased 14.0% year-over-year.
- Peak return on equity (roe) was recorded in FY2021.
- Lowest return on equity (roe) in the period was in FY2011.
Company context
Key Data Points
- Altman Z-Score -0.62 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Return on Equity (ROE)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | -39.2% | +14.0% |
| FY2024 | -45.6% | +0.3% |
| FY2023 | -45.7% | +6.2% |
| FY2022 | -48.8% | -124.6% |
| FY2021 | -21.7% | +51.8% |
| FY2020 | -45.1% | +44.4% |
| FY2019 | -81.1% | +31.2% |
| FY2018 | -117.8% | -242.4% |
| FY2017 | -34.4% | +96.9% |
| FY2011 | -1105.5% | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026